Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Observation of Pain During Radiofrequency Ablation of Saphenous Vein,and Analysis of Related Factors

28 juin 2026 mis à jour par: Chunshui He, Chengdu University of Traditional Chinese Medicine
Objective: This study is a single-center prospective observational study, which recorded the pain scores of patients at four time nodes during surgery (puncture and catheterization, injection of swelling fluid, radiofrequency generator work, and end of surgery), and analyzed the correlation between intraoperative pain and age, gender, BMI and other factors, so as to summarize and improve the details of surgery and reduce patients' intraoperative pain.

Aperçu de l'étude

Description détaillée

Although the global vascular surgeons have made significant progress in the study of RFA in the treatment of VVs, there are still many unknown areas to be explored, and the current research mainly focuses on the surgical effect of RFA and related complications, while the research on intraoperative pain is relatively scarce. First of all, RFA does not have a clear definition of intraoperative pain in the treatment of varicose veins of the lower extremities, so it has not received enough attention in clinical practice, and many doctors regard the success of surgery as the end point of treatment, but ignore the impact of intraoperative pain on the patient's surgical experience. In addition, with the continuous progress of varicose vein surgery of the lower extremities, the anesthesia method has also changed from general anesthesia to combined spinal-epidural block to today's local anesthesia, the swollen anesthetic solution is the main anesthetic drug used in RFA surgery, and the infiltration of the swollen anesthetic fluid around the saphenous vein is the key to the success of RFA, but paradoxically, this is also the most intense part of the patient's pain, the swollen fluid is usually a crystalloid solution containing local anesthetic and epinephrine, which is acidic in nature, which is also the main reason for the "tingling" during skin infiltration , A Cochrane review noted that adjusting the pH of lidocaine solution by adding sodium bicarbonate significantly reduced the pain reported on a 10 cm visual analogue scale (VAS) during skin infiltration, and that the temperature of the swollen anesthetic solution also had an effect on pain during skin infiltration, Bell et al. and Alonso et al. In a prospective randomized controlled trial, it was found that heating the local anesthetic solution to 37°C and 42°C reduced pain sensation, and heating the local anesthetic solution containing epinephrine to near body temperature was effective in reducing the pain of local anesthetic infiltration in patients, however, in a randomized clinical trial in 2018, patients were divided into cold swollen fluid group (4 °C) and room temperature swollen fluid group (24 °C), and the authors found that patients in the cold swollen fluid group had less pain during and after RFA, The amount of postoperative analgesics was significantly reduced. Therefore, the patient's pain during RFA has become a problem that we must pay attention to, and the operator should pay attention to the details and pay attention to the patient's intraoperative condition during RFA, so as to reduce the patient's intraoperative pain and give the patient a better surgical experience.

Type d'étude

Observationnel

Inscription (Réel)

155

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Sichuan
      • Chengdu, Sichuan, Chine, 610000
        • Hospital of Chengdu University of Traditional Chinese Medicine

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Patients diagnosed with primary VVs from April 2023 to September 2023 who were admitted to the hospital and underwent RFA treatment for the main trunk of the saphenous vein

La description

Inclusion Criteria:

  1. Age≥ 18 years old, ≤ 90 years old;
  2. the patient's life expectancy is greater than 12 months;
  3. The clinical diagnosis is primary VVs, CEAP classification C2-C6, and the GSV segment needs to be treated, including pain, burning sensation, heaviness, fatigue, itchy skin, night cramps and other clinical symptoms;
  4. Doppler ultrasound confirmed that the diameter of GSV was greater than 3mm and less than 12mm when standing;
  5. Doppler ultrasound confirms that GSV is located in the saphenofascia or the distance between GSV and the skin surface is >1cm;
  6. radiofrequency ablation treatment only for unilateral GSV walking area;
  7. The patient is willing to cooperate with the completion of the examination specified in the protocol.

Exclusion Criteria:

  1. GSV thrombosis, or combined with deep vein thrombosis, or previous history of deep vein thrombosis and pulmonary embolism;
  2. patients with recurrence after prior VVs-related surgery (C2r);
  3. the GSV trunk is severely distorted, and it is expected that the catheter will not be able to pass;
  4. Severe ischemia of the lower limbs, Ankle brachial pressure index (ABPI) < 0.8;
  5. Known allergy to the drugs and device materials involved in the study;
  6. Previously implanted with a pacemaker or defibrillator, and currently receiving regular anticoagulation therapy (such as warfarin, heparin);
  7. Pregnant or lactating females;
  8. Patients who are unable or unwilling to participate in the study;
  9. Participating in the research of other drugs or devices;
  10. Skin malignancies other than non-melanoma that are being treated;
  11. daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain caused by venous disease;
  12. The investigator judged that endovenous treatment was not suitable;

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Observation of Pain During Radiofrequency Ablation of Saphenous Vein,and Analysis of Related Factors
Among the 155 patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery, and the procedure of radiofrequency ablation of the saphenous vein trunk supplemented with sclerotherapy was applied to record the data of the operating room temperature, puncture site, and the VAS scores of the puncture and tube placement, injection of the swelling fluid, radiofrequency generator, and the end of the procedure. The patients' intraoperative pain scores were descriptively analyzed to assess the degree of intraoperative pain, and non,parametric tests were applied to analyze the correlation between preoperative and intraoperative factors and intraoperative pain.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Puncture catheterization
Délai: At the time of surgery
The pain during puncture and catheterization mainly comes from needle breakage, local anesthetic infiltration and vascular sheath insertion, the 7F vascular puncture sheath group was used in this study, the diameter of the puncture needle is 1.27mm, the pain during skin puncture is stronger than that of the syringe needle used for intravenous or intramuscular injection, there is a well-designed randomized controlled use of an automatic injection device to standardize the injection parameters, and the use of smaller needles also forces the injector to slow down the injection rate, which can reduce the pain of the patient
At the time of surgery
Inject swollen fluid
Délai: At the time of surgery
In this study, a 0.7mm needle was used to inject lidocaine into the skin around the puncture point, which can be replaced with a 0.5mm needle to slow down the injection rate of lidocaine, reduce the stinging sensation of the patient, and place the vascular sheath after the local anesthetic infiltrates the skin, which can slightly reduce the pain of the vascular sheath entering the blood vessel through the skin. Similarly, a 0.7mm needle is used to inject swelling fluid from the puncture point along the main trunk of the saphenous vein, the longer the length of the patient's ablation vein, the number of skin breaks will increase, but the patient's pain will not increase with the accumulation of skin breaks, and the operator can reduce the pain of the patient's injection of swelling fluid by squeezing, pressing, stretching the skin, and inserting the needle vertically
At the time of surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 juillet 2024

Achèvement primaire (Réel)

1 septembre 2024

Achèvement de l'étude (Réel)

1 septembre 2024

Dates d'inscription aux études

Première soumission

29 juillet 2024

Première soumission répondant aux critères de contrôle qualité

28 juin 2026

Première publication (Réel)

6 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 juin 2026

Dernière vérification

1 juillet 2024

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner